Jubilant Organosys, an integrated pharmaceutical major and the country's largest custom research and manufacturing company, on Tuesday announced a multi-million dollar long-term agreement with Syngenta to supply pyridines.
The contract starts early 2008 and covers an extension period of up to five years, during which Jubilant will continue supplying the products to Syngenta.
Chairman and MD Shyam S Bhartia and co-chairman and MD Hari S Bhartia of Jubilant Organosys said: "The long-term supply agreement for pyridines to Syngenta, is a significant recognition of our global leadership position in pyridines and its derivatives. Besides providing an additional and a stable stream of revenue and earnings to our custom research and manufacturing segment, this multi-year contract would help demonstrate and establish Jubilant's global credentials as the preferred outsourcing partner to life science companies."
Pyridine and its derivatives represent a high growth area for Jubilant within the pharmaceutical and life science products business. With an integrated setup, the company retains global leadership in the manufacture of these key intermediates that are used to make several pharmaceutical and agro-chemical products.
The company has more than 150 pyridine derivatives in its product portfolio, which find application in about 229 active pharmaceutical ingredients and 17 agro-chemicals. "This contract is not just an extension of our existing multi-year relationship with Syngenta, but also proves our ability to provide enhanced value to our customers through the delivery of high-quality products and customer service," a company statement said.
Pyridines and their derivatives form part of Jubilant's growth platform under its custom research and manufacturing segment, where it offers proprietary products and exclusive synthesis options to life science companies.
Jubilant also has the largest integrated manufacturing facilities for these products in India. The company had recently expanded its production capacity for pyridines and picolines to 42,000 TPA and this contract would significantly improve the use of the additional capacity.